The record · constituent by constituent
What the BPC-157 and TB-500 literature actually establishes
Each finding below comes from one peptide's own studies. We label which leg of the blend it belongs to — and where the combination has no evidence at all.
BPC-157 and TB-500: What the Two Peptides Are and Who Studies Them
BPC-157 TB-500 research splits cleanly into two literatures that almost never meet. BPC-157 is studied mostly by tissue-repair and gastrointestinal pharmacology groups; the foundational body of work comes substantially from one research group (Sikiric and colleagues), a concentration that newer reviews explicitly flag when weighing independent replication [11]. TB-500's evidence is mostly the evidence of its parent protein, Thymosin Beta-4, studied in wound-healing, cardiac, and regenerative-medicine settings [7].
That split matters for reading the blend honestly. When a source says "TB-500 promotes wound healing," the underlying data were usually generated with full-length Thymosin Beta-4 (about 4963 Da), not the Ac-LKKTETQ heptapeptide (about 889 Da) that is actually sold [8]. The fragment was first characterized in a doping-control context, which pinned down its precise identity as the N-acetylated 17-23 fragment — distinct from the full protein it is drawn from [8].
So "who studies them" has a two-part answer. The peptides as research molecules are studied by legitimate academic groups. The blend as a product is discussed largely in athlete forums and research-supplier copy, where the careful single-compound, animal-model boundaries of the actual science tend to get lost. For the pathway-level detail behind each leg of the pairing, see the BPC-157 TB-500 cytoprotection research page.
What BPC-157 and TB-500 Have Been Studied For
BPC-157 TB-500 benefits, as discussed online, run far ahead of what the published record supports — so it is worth stating plainly what each peptide has actually been studied for, and in what species.
For BPC-157, the preclinical literature covers tendon, ligament, muscle, and bone repair, wound and soft-tissue healing, gastrointestinal cytoprotection, and angiogenesis [5]. The flagship result: in a fully transected rat Achilles tendon, BPC-157 (administered at 10 microg/kg or 10 ng/kg intraperitoneally) accelerated healing across biomechanical, functional, microscopic, and macroscopic measures, and in culture it reversed 4-hydroxynonenal-induced growth inhibition of tendocytes into stimulation [5].
For TB-500, the studied effects are those of Thymosin Beta-4: actin binding, cell migration, anti-scarring (fewer myofibroblasts), anti-inflammatory signaling, and angiogenesis [7]. In animal wound models, Thymosin Beta-4 increased re-epithelialization, contraction, collagen deposition, and angiogenesis [7].
Every item in that list is single-compound and overwhelmingly rodent. None of it is a blend result. A 2025 systematic review of BPC-157 in orthopaedic sports medicine included 36 studies — 35 preclinical and only one human — found "no clinical safety data," and rated the evidence at the lowest tiers (level IV-V) [9]. A 2025 narrative review reached the same conclusion: broad preclinical support, extremely limited human data, and a recommendation to treat BPC-157 as investigational [11]. A 2026 Sports Medicine review of approved and unapproved peptide therapies — listing both BPC-157 and TB-500 / thymosin beta-4 — found that many unapproved peptides show favorable tissue-repair outcomes in animal models but that rigorous human safety data are scarce, with potential for serious harm, and that such compounds operate largely outside regulatory oversight [10].
Tendon, Muscle, and Wound: the Findings That Hold
Tendon and Ligament Findings
In animal models, BPC-157 accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, and microscopic measures [5] and enhanced tendon-fibroblast outgrowth, survival, and migration via FAK-paxillin signaling [4]. These are preclinical, single-compound results, not human or combination evidence.
Muscle Repair Findings
Preclinical studies report BPC-157 aiding muscle and tendon repair through cytoprotective and growth-hormone-receptor mechanisms [3]; Thymosin Beta-4 (TB-500's parent) supports cell migration relevant to muscle repair [7]. Findings are animal-model and single-compound; the blend has no controlled muscle-recovery trial. A cautionary note: in dystrophin-deficient mdx mice, chronic Thymosin Beta-4 increased regenerating fibers but did not improve strength, cardiac function, or fibrosis [7].
Wound and Soft-Tissue Findings
In animal wound models, Thymosin Beta-4 (TB-500's parent) increased re-epithelialization, contraction, collagen deposition, and angiogenesis [7], and BPC-157 shows multi-tissue cytoprotection [5]. These are preclinical, single-compound results; the blend itself has no controlled wound-healing trial.
Has Synergy Been Demonstrated?
No. No peer-reviewed study has defined a synergy ratio, dose, or endpoint for BPC-157 and TB-500 given together. The 2025 systematic review of BPC-157 — 36 studies, only one human, "no clinical safety data" — makes no mention of TB-500 or combination use at all [9]. "Synergy" is an extrapolation from each peptide's separate, largely non-overlapping mechanism [1][6].
The BPC-157 + TB-500 Stack: Combined-Use Rationale and the Evidence Gap
The BPC-157 TB-500 stack is the same construct under a different word. The combined-use rationale is the complementary-mechanism story — local cytoprotection plus cytoskeletal migration [1][6] — and the evidence gap is total at the combination level: no head-to-head study, no defined ratio, no synergy endpoint. Fixed-ratio vials and "loading then maintenance" protocols circulate widely but have no basis in any controlled trial [8].
Human Trials on the Combination
There are no controlled clinical trials of the BPC-157 + TB-500 combination for any indication. Human data exist only for the individual constituents and are thin: BPC-157 has three small pilot studies (a two-person intravenous safety pilot, an intra-articular knee-pain case series, and a 12-patient intravesical interstitial-cystitis pilot), and "TB-500" human data are actually for full-length Thymosin Beta-4, not the heptapeptide [9]. The known side effects and safety signals — most notably the tumor-angiogenesis consideration tied to Thymosin Beta-4 — are gathered on the FAQ page.